Advertisement
Screener

Inhibikase Therapeutics, Inc. (IKT) Cash Flow Breakdown

Inhibikase Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Inhibikase Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $27.79M went out.
  • Fiscal year ended 2025-12-31: from investing, $2.05M came in.
  • Fiscal year ended 2025-12-31: from financing, $108.46M came in.
  • Fiscal year ended 2025-12-31: change in cash, $82.73M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$27.79M$2.05M$107.62M$845.47K*$82.73M
2024-12-31-$19.15M-$37.00M$103.48M$47.33M
2023-12-31-$18.09M$11.66M$8.54M$1.98M
2022-12-31-$17.35M-$16.01M$0.00-$33.56M
2021-12-31-$14.30M$0.00$78.50K$41.02M*$26.80M
2020-12-31-$1.13M$0.00$4.87K$15.06M*$13.94M

Each quarter (3 month)

Quarter endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$12.44M*-$5.91M*$0.00*
2026-03-31-$12.06M-$80.48M$2.90M-$89.65M
2025-12-31-$7.52M*-$98.85K*$107.62M*$947.98K*
2025-09-30-$10.59M*-$28.75M*$0.00*
2025-06-30-$5.57M*$9.84M*$150.00*
2025-03-31-$4.10M$21.05M$0.00$16.95M
2024-12-31-$5.35M*-$38.76M*$99.68M*
2024-09-30-$4.88M*$2.53M*$181.95K*
2024-06-30-$5.05M*$2.54M*$3.21M*
2024-03-31-$3.87M-$3.31M$397.61K-$6.81M
2023-12-31-$3.44M*-$2.12M*$452.00*
2023-09-30-$4.11M*$17.06M*$70.00*
2023-06-30-$4.57M*$2.55M*$7.54M*
2023-03-31-$5.97M-$5.84M$1.00M$7.58M*-$3.23M
2022-12-31-$3.56M*$4.96M*$0.00*
2022-09-30-$5.50M*-$20.93M*$0.00*
2022-06-30-$4.36M*-$43.09K*$0.00*
2022-03-31-$3.93M$0.00$0.00-$4.14M
2021-12-31-$4.10M*$0.00*$0.00*$0.00*
2021-09-30-$2.02M*$0.00*$0.00*-$14.25K*
2021-06-30-$4.25M*$34.36K*$41.44M*
2021-03-31-$3.93M$0.00-$4.34M
2020-12-31-$946.53K*$0.00*$0.00*$14.88M*
2020-09-30$75.52K*$0.00*
2020-06-30-$2.91K*$0.00*
2020-03-31-$255.43K$4.87K-$5.31K

Similar stocks

Stock NameCountryMarket CapPE Ratio
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34